Uterine Serous Carcinoma (USC) is an aggressive form of serous endometrial cancer that presents with severe vaginal bleeding, pain in the pelvic region, and decreased quality of life. There is a 50% chance of recurrent or relapsed USC even after getting the right treatment.
Revive Research Institute is conducting a clinical research study to assess the safety and efficacy of an investigational drug to treat recurrent or persistent USC in adult women. Our goal is to use the investigational drug to inhibit the growth of related cancer cells and cancerous protein kinases.
- Female adults 18 years of age or older
- Confirmation of recurrent or persistent USC
- Comply with study procedures
Our group of licensed and certified physicians will be keeping track of the patient’s progress throughout the study and will address any concerns or queries that arise regarding the research trial. The investigational treatment is free for the duration of the clinical trial and insurance is not required. All patient records and information will be kept secure and confidential. The patient will also receive compensation for their time and involvement.